

# Shilpa Medicare Limited



Innovating for  
affordable healthcare

**Manufacturers and Exporters of Bulk Drugs**

"Shilpa House" # 12-6-214/A1, Hyderabad Road,  
RAICHUR - 584 135. Karnataka, India.

Phone : +91-8532 - 238704, Fax : +91-8532-238876

E-mail : info@vbshilpa.com Website : www.vbshilpa.com

GST NO : 29AADCS8788F1Z0

CIN No. L85110KA1987PLC008739

Dated: 25.10.2019

Corporate Relationship Department,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
**Mumbai-400 001**

National Stock Exchange of India Limited  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block  
Bandra Kurla Complex, Bandra (E)  
**MUMBAI-400 051**

Dear Sir/Madam,

**Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.**  
**Ref: Stock Code: NSE: SHILPAMED/BSE-530549**

\*\*\*\*\*

We hereby inform that the Company has received US FDA 'Establishment Inspection Report (EIR)' on 24 Oct 2019, for the Finished Dosage Formulation Facility (Sterile and Non-sterile Dosage Forms) located at S-20 to S-26, Pharmaceutical Formulations SEZ, APIIC, Jadcherla, Telangana State, India.

The company's finished dosage form facility was inspected by US FDA from 29<sup>th</sup> August to 6<sup>th</sup> September, 2019. FDA has concluded the inspection, with determination that the inspection classification of this facility is "voluntary action indicated" ("VAI"). This facility is in acceptable state of compliance with regards to current good manufacturing practice (CGMP).

This is for your information and doing the needful.

With Regards,

For **SHILPA MEDICARE LIMITED**



**V.V. Krishna Chaitanya**  
**Company Secretary & Compliance Officer**